Chemotherapy Drug Allergy: Platinum Reactions, Desensitization & Care

Platinum compounds — carboplatin, cisplatin, and oxaliplatin — cause IgE-mediated hypersensitivity that develops through cumulative exposure, unlike penicillin allergy which can manifest on initial exposure after prior sensitization. Each platinum treatment cycle allows the immune system to build drug-specific IgE antibodies gradually against the platinum-protein hapten complex. Once sufficient IgE accumulates on mast cell and basophil surfaces across cycles, the next exposure triggers cross-linking and acute degranulation. This mechanism explains why carboplatin reactions typically emerge after 8 or more successful cycles, with the risk reaching up to 27% by cycle 15 and beyond. Proactive skin testing before later cycles can identify emerging sensitization before clinical reactions occur, enabling desensitization planning.

Developed by Dr. Mariana Castells at Brigham and Women's Hospital, this protocol uses three bags of the prescribed chemotherapy at progressively higher concentrations (1/100th, 1/10th, and full strength of the total target dose). Starting with a very small dose, the infusion rate is doubled every 15 minutes across 12 steps over approximately 6 hours. Premedication includes diphenhydramine, famotidine, acetaminophen, and montelukast. The protocol achieves greater than 95% success across 413 desensitizations in 98 patients, but must be repeated for every subsequent cycle.

For taxanes, it is often the vehicle rather than the drug molecule causing the hypersensitivity reaction. Paclitaxel is formulated in Cremophor EL — polyoxyethylated castor oil — and docetaxel in polysorbate 80; both vehicles directly activate complement pathways and mast cells through non-IgE mechanisms, producing anaphylactoid reactions. Nab-paclitaxel (Abraxane), an albumin-bound formulation, avoids Cremophor entirely and dramatically reduces hypersensitivity rates as a result. For platinum compounds, the drug molecule itself is the allergen forming IgE-inducing hapten-protein complexes. This distinction is clinically transformative: vehicle-mediated taxane reactions can often be resolved by switching to a Cremophor-free formulation or using aggressive premedication, while platinum reactions require formal desensitization or agent substitution.

Yes, carboplatin intradermal skin testing at a standardized concentration of 10 mg/mL has been validated with a negative predictive value of 81 to 98.5%, making it one of the most reliable drug allergy skin tests available for any drug class. A negative skin test reliably predicts tolerance to the next carboplatin cycle, enabling the majority of tested patients to proceed without desensitization. Skin testing can be performed proactively before later treatment cycles — typically starting from cycle 7 onward — to identify emerging sensitization before a clinical anaphylaxis event disrupts treatment. A positive result does not preclude continued carboplatin therapy but identifies patients who require the BWH 12-step desensitization protocol. Cisplatin and oxaliplatin have separate cross-reactivity considerations and their own skin test protocols.

Native E. coli L-asparaginase causes hypersensitivity in 10 to 45% of patients — one of the highest immunogenicity rates of any chemotherapy drug. Erwinia asparaginase (Erwinaze, Rylaze), derived from Erwinia chrysanthemi bacteria, is the standard alternative with limited cross-reactivity to E. coli asparaginase because it is antigenically distinct. PEGylated asparaginase (pegaspargase, Oncaspar or Asparlas) reduces immunogenicity compared to native E. coli form, with reaction rates of approximately 10 to 18%, but carries cross-reactivity with the PEG component. Patients with PEG allergy require specific risk assessment before receiving pegaspargase, including skin testing with stepwise PEG concentrations. The PEG anaphylaxis story connects asparaginase allergy to laxative allergy and mRNA vaccine allergy — all share polyethylene glycol as the sensitizing epitope.

Yes, Cremophor EL (polyoxyethylated castor oil) is the vehicle used in both conventional paclitaxel and IV cyclosporine — an immunosuppressant used in transplant medicine. This means that a patient who reacted to IV cyclosporine may have reacted to the vehicle rather than the drug itself, and that same patient carries elevated Cremophor reactivity risk when receiving paclitaxel. Clinicians prescribing either drug should cross-reference the patient's full medication reaction history across drug classes. The principle applies broadly: vehicle-mediated reactions can sometimes be bypassed entirely through reformulation. Switching from conventional paclitaxel to nab-paclitaxel (Abraxane, albumin-bound) eliminates Cremophor exposure. For IV cyclosporine-sensitive patients, oral cyclosporine formulations avoid the Cremophor vehicle problem entirely.

Oxaliplatin occupies a distinct position among platinum compounds because its hypersensitivity mechanism includes both IgE-mediated features and non-IgE immune components not seen with carboplatin or cisplatin. While carboplatin HSR is predominantly classical IgE-mediated anaphylaxis through platinum-hapten sensitization, oxaliplatin can cause acute hemolytic anemia and thrombocytopenia in addition to the typical urticaria and bronchospasm — suggesting a Type II cytotoxic immune component alongside Type I features. An HLA-DRB*12:01 pharmacogenomic association has been identified for oxaliplatin hypersensitivity, in contrast to carboplatin where no HLA associations are established. Cross-reactivity between carboplatin and oxaliplatin is lower than carboplatin-cisplatin cross-reactivity due to the different platinum coordination chemistry of oxaliplatin, making oxaliplatin a potential alternative for some carboplatin-allergic patients when skin testing is negative.

PEGylated asparaginase (pegaspargase, Oncaspar or Asparlas) contains polyethylene glycol as a conjugation agent to extend the enzyme's half-life and reduce native E. coli asparaginase immunogenicity. When patients develop reactions to pegaspargase, the PEG moiety itself may be the sensitizing antigen — not the asparaginase enzyme. This creates cross-reactivity with other PEG-containing products including certain laxatives (polyethylene glycol 3350, Miralax), mRNA COVID-19 vaccines (which use PEGylated lipid nanoparticles), and some injectable medications and IV contrast agents. The clinical implication is that PEG allergy should be suspected when a patient reacts to multiple unrelated products sharing polyethylene glycol as an excipient, and PEG-specific skin testing with stepwise concentrations should be performed before rechallenge with any PEG-containing formulation.